Clinical Pharmacology (Phase I-IIa)
Overview |
 |
For more than 30 years, Covance has helped pharmaceutical and biotech clients manage the critical transition from nonclinical studies to clinical trials. Once efficacy in the patient population is demonstrated, the value of a new molecular entity (NME) increases dramatically.
Our global Clinical Pharmacology organization (Phase I-IIa) delivers timely, accurate data that enables you to make decisions about the safety and efficacy of your compound early in the clinical development cycle. With ten clinical research units in the United States and United Kingdom, and the global support of a full-service CRO, Covance is uniquely positioned to guide your drug candidate into First-in-Human trials through Proof-of-Concept to commercial launch. |
|
 |
|
|
|
|
|
